Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

被引：5
|
作者：
Prat, Aleix
Modi, Shanu
Tsurutani, Junji
Cameron, David
Harbeck, Nadia
Garrido, Charo
Karnoub, Maha
Hsu, Ching
Feng, Wenquin
Yung, Lotus
Wang, Yibin
Gambhire, Dhiraj
Ford, Shirin K.
Vitazka, Patrik
Ueno, Naoto T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-HER2-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2-18
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
  • [42] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [43] HER2-low breast cancer: where are we?
    Molinelli, Chiara
    Jacobs, Flavia
    Marchio, Caterina
    Pitto, Francesca
    Cosso, Maurizio
    Spinaci, Stefano
    de Azambuja, Evandro
    Schettini, Francesco
    Agostinetto, Elisa
    Lambertini, Matteo
    BREAST CARE, 2022, 17 (06) : 533 - 544
  • [44] Epidemiology of HER2-low breast cancer in Lithuania
    Cesas, A.
    Poskiene, L.
    Valkiuniene, R. B.
    Radvinskiene, L.
    Lege, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 103 - 104
  • [45] HER2-Low Breast Cancer: a New Subtype?
    Corti, Chiara
    Giugliano, Federica
    Nicolo, Eleonora
    Tarantino, Paolo
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) : 468 - 478
  • [46] HER2-Low Breast Cancer: Now and in the Future
    Kang, Sora
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 700 - 720
  • [47] Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy
    Paulissen, Jeroen Hendrikus Jacobus
    van Schoonhoven, Alexander Victor
    Olin, Emma
    Postma, Arjan Jacobus
    Mbanya, Zacharie
    Dunton, Kyle John
    Postma, Maarten Jacobus
    van Hulst, Marinus
    Freriks, Roel Donald
    ADVANCES IN THERAPY, 2025, 42 (01) : 322 - 333
  • [48] CHMP recommends Approval of ENHERTU® in the EU for Female Patients with HER2-low metastatic Breast Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [49] The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
    Gamrani, Sanaa
    Akhouayri, Laila
    Boukansa, Sara
    Karkouri, Mehdi
    El Fatemi, Hinde
    BREAST JOURNAL, 2023, 2023
  • [50] Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers
    Bieth, Claire
    Benderra, Marc Antoine
    Tichoue, Herve Foka
    Houari, Samy
    Hassani, Lamia
    Ghebriou, Djamel
    Seknazi, Lauren
    Barthere, Xavier
    Prebet, Coralie
    De Forceville, Louise
    Lotz, Jean-Pierre
    Gligorov, Joseph
    Jamelot, Mathieu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345